{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:21:15Z","timestamp":1763529675642,"version":"3.45.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a greater risk of complications from severe COVID-19 in immunocompromised patients with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs), as well as a diminished vaccine response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this exploratory, observational study, we recruited 28 patients with Relapsing Remitting MS (RRMS, n=24) or Secondary Progressive MS (SPMS, n=4), that were receiving treatment with either natalizumab or fumarates (diroximel or dimethyl) prior to baseline sample collection. Blood samples were collected before vaccination (baseline), between 4 weeks and 6 months post vaccination, and post booster administration. A multiplex bead immunoassay (MBI) was used to measure anti-Spike IgG, while IFN\u03b3 and IL-2 ELISpot assays were used to determine T cell activation. A 35-color spectral flow cytometry panel was used to phenotype bulk B and T cells and SARS-CoV-2-specific T cells, while dimensionality reduction was performed for further phenotypic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed a significantly increased absolute lymphocyte count (ALC) (p=0.0003) in natalizumab-treated pwMS when compared to fumarate-treated pwMS primarily due to increased circulating CD19+ B cells. Fumarate-treated pwMS exhibited a diminished Th1\/Th2 ratio when compared to natalizumab-treated pwMS (p=0.0004) or healthy controls (p=0.0745), while natalizumab treatment marginally increased the Th1\/Th2 ratio compared to healthy controls (p=0.1311). The observed increase in B cells in natalizumab-treated pwMS were predominantly memory B cells, and double negative (DN) B cells. However, no significant differences between the treatment groups were seen in terms of Spike IgG titers following the initial vaccination course or booster dose, nor in SARS-CoV-2-specific CD4+ responses, all of which remained robust for at least 6 months post-vaccination. The magnitude of humoral and cellular immune responses in both treatment groups were comparable to vaccinated healthy controls. Additionally, SARS-CoV-2 spike-specific CD4+ T cell phenotyping revealed a Th2 dominant response to booster dose in natalizumab-treated pwMS (p=0.0485) but not fumarate-treated pwMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>pwMS treated with natalizumab or fumarates exhibit similarly robust and durable SARS-CoV-2 specific T cell and humoral responses following vaccination and booster dose. DMT-treated pwMS showing comparable responses to healthy individuals following initial vaccination supports the notion that treatment with these specific DMTs does not diminish strong, long-lasting immunity conferred by COVID-19 vaccination, despite the phenotypic differences modulated by each therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1568157","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:18:11Z","timestamp":1763529491000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses"],"prefix":"10.3389","volume":"16","author":[{"given":"Ryan","family":"Curtin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogambigai","family":"Velmurugu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatoumatta","family":"Dibba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Nyovanie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mieles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Avila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen","family":"Smrtka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yury","family":"Patskovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg J.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Krogsgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","article-title":"Features, evaluation, and treatment of coronavirus (COVID-19)","volume-title":"StatPearls","author":"Cascella","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.250.271","article-title":"The coronavirus disease 2019 (COVID-19) pandemic","volume":"250","author":"Baloch","year":"2020","journal-title":"Tohoku J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Moreira","year":"2021","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19581-y","article-title":"SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study","volume":"12","author":"Takeuchi","year":"2022","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02414-4","article-title":"SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease","volume":"29","author":"Barnes","year":"2023","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5888\/pcd18.210123","article-title":"ORIGINAL RESEARCH underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020-March 2021","volume":"18","author":"Kompaniyets","year":"2021","journal-title":"Prev Chronic Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad174","article-title":"COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the future","volume":"228","author":"Hall","year":"2023","journal-title":"J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.796482","article-title":"B- and T-cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: immunological patterns and clinical implications","volume":"12","author":"Iannetta","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04143.x","article-title":"T cells in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"162","author":"Fletcher","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B cells in multiple sclerosis and related disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4137\/PMC.S13213","article-title":"Multiple sclerosis: overview of disease-modifying agents","volume":"6","author":"Finkelsztejn","year":"2014","journal-title":"Perspect Medicin Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00005","article-title":"Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis","volume":"9","author":"Mills","year":"2018","journal-title":"Front Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1756286418773025","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s43856-024-00448-4","article-title":"Humoral and cellular immune responses to COVID-19 mRNA vaccines in immunosuppressed liver transplant recipients","volume":"4","author":"Nogimori","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.920227","article-title":"Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave","volume":"13","author":"Aiello","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","article-title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2","volume":"5","author":"Catanzaro","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156978","article-title":"Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function","volume":"7","author":"Sabatino","year":"2022","journal-title":"JCI Insight"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e47578","DOI":"10.1371\/journal.pone.0047578","article-title":"Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis","volume":"7","author":"Bornsen","year":"2012","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0160277","DOI":"10.1371\/journal.pone.0160277","article-title":"Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation","volume":"11","author":"Iannetta","year":"2016","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1212\/NXI.0000000000000183","article-title":"Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis","volume":"3","author":"Gross","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40120-023-00448-x","article-title":"COVID-19 vaccine response in people with multiple sclerosis treated with dimethyl fumarate, diroximel fumarate, natalizumab, ocrelizumab, or interferon beta therapy","volume":"12","author":"Jaber","year":"2023","journal-title":"Neurol Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"104102","DOI":"10.1016\/j.ebiom.2022.104102","article-title":"Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"EBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"20552173231191170","DOI":"10.1177\/20552173231191170","article-title":"Vaccine response in people with multiple sclerosis treated with fumarates","volume":"9","author":"Tremblay","year":"2023","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165111","article-title":"T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis","volume":"8","author":"Wolf","year":"2023","journal-title":"JCI Insight"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050183","article-title":"Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine","volume":"13","author":"Dominelli","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52081","article-title":"Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination","volume":"11","author":"Kister","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31424-3","article-title":"Hierarchy of human IgG recognition within the immunome","volume":"8","author":"Radke","year":"2018","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26346","article-title":"Cellular and humoral immunity to SARS-coV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: A multi-ethnic observational study","volume":"91","author":"Kister","year":"2022","journal-title":"Ann Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1038\/s41467-024-47013-0","article-title":"Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients","volume":"15","author":"De Biasi","year":"2024","journal-title":"Nat Commun"},{"key":"B39","volume-title":"flowCore: flowCore: Basic structures for flow cytometry data. R package version 2.12.2","author":"Ellis B","year":"2023"},{"key":"B40","unstructured":"R: A language and enviroment for statistical computing. R foundation for statistical computing\n          \n          \n            \n              team\n              R\n            \n          \n          \n          2004"},{"key":"B41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"R: A language for data analysis and graphics","volume":"5","year":"1996","journal-title":"J Comput Graphical Stat"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0654-x","article-title":"Orchestrating single-cell analysis with Bioconductor","volume":"17","author":"Amezquita","year":"2020","journal-title":"Nat Methods"},{"key":"B43","unstructured":"Crowell H\n              ZV\n            \n            \n              Chevrier\n              S\n            \n            \n              Robinson\n              M\n            \n          \n          CATALYST: Cytometry data analysis tools\n          \n          2023"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"B45","volume-title":"SVA: Surrogate Variable Analysis","author":"Leek JT","year":"2023"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1088\/1742-5468\/2008\/10\/P10008","article-title":"Fast unfolding of communities in large networks","author":"Blondel","year":"2008","journal-title":"J Stat Mechanics Theory Exp"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1802.03426","article-title":"UMAP: uniform manifold approximation and projection for dimension reduction","author":"Leland McInnes","year":"2018","journal-title":"arXiv"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12974-019-1593-2","article-title":"Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients","volume":"16","author":"Traub","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B50","doi-asserted-by":"publisher","first-page":"102987","DOI":"10.1016\/j.msard.2021.102987","article-title":"Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis","volume":"52","author":"Cuculiza Henriksen","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13615","article-title":"Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity","volume":"205","author":"Li","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.immuni.2021.03.013","article-title":"Positive selection of IgG(+) over IgM(+) B cells in the germinal center reaction","volume":"54","author":"Sundling","year":"2021","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27688","article-title":"Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review","volume":"94","author":"Notarte","year":"2022","journal-title":"J Med Virol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e17341","DOI":"10.15252\/emmm.202217341","article-title":"Functions of double-negative B cells in autoimmune diseases, infections, and cancers","volume":"15","author":"Chung","year":"2023","journal-title":"EMBO Mol Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41467-022-29753-z","article-title":"T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy","volume":"13","author":"Garaud","year":"2022","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31254","article-title":"A little stress is good:: IFN-\u03b3, demyelination, and multiple sclerosis","volume":"117","author":"Lees","year":"2007","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.769442","article-title":"T-cell repertoire characteristics of asymptomatic and re-detectable positive COVID-19 patients","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030564","article-title":"The influence of cross-reactive T cells in COVID-19","volume":"12","author":"Eggenhuizen","year":"2024","journal-title":"Biomedicines"},{"key":"B59","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.immuni.2023.03.005","article-title":"Spheromers reveal robust T cell responses to the Pfizer\/BioNTech vaccine and attenuated peripheral CD8(+) T cell responses post SARS-CoV-2 infection","volume":"56","author":"Gao","year":"2023","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12929","article-title":"The roles of resident, central and effector memory CD4 T-cells in protective immunity following infection or vaccination","volume":"154","author":"Gray","year":"2018","journal-title":"Immunology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk5845","article-title":"Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool","volume":"8","author":"Weber","year":"2023","journal-title":"Sci Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1568157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:18:13Z","timestamp":1763529493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1568157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2025.1568157"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1568157","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1568157"}}